Developing functional membrane protein arrays for highly efficient drug screening
Developing functional membrane protein arrays for highly efficient drug screening
批准号:
8200663
负责人:
XICHUN ZHOU
金额:
$15.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-09-15 至 2013-03-31
关键词:
AddressAntibodiesAreaBiochemicalBiologicalBiological AssayBiomedical ResearchCardiacCell membraneCell physiologyCellsCommunicable DiseasesDNADehydrationDetectionDevelopmentDiabetes MellitusDiseaseDrug Delivery SystemsEnvironmentFeasibility StudiesFilmFluorescence Resonance Energy TransferFunctional disorderFutureG-Protein-Coupled ReceptorsGlassHeart DiseasesImmobilizationInflammationInflammatoryInvestigationKidney DiseasesLaboratory ResearchLaboratory StudyLeadLifeLigand BindingLipid BilayersLipidsMalignant NeoplasmsMarketingMeasuresMembraneMembrane LipidsMembrane ProteinsMethodsMicroarray AnalysisModelingOrganismPatternPeptidesPharmaceutical PreparationsPhasePlayPreclinical Drug EvaluationPrintingProtein ArrayProtein BindingProtein MicrochipsProteinsReportingResearchRoboticsRoleScreening procedureSignal PathwaySpottingsSystemTherapeuticTherapeutic AgentsVariantVesiclebasedrug developmentdrug discoveryinterestphase 1 studyprotein functionresearch and developmentsmall moleculesuccesstherapeutic targettool
中文摘要
描述(由申请人提供):膜蛋白是细胞间信号通路的重要组成部分。绝大多数的小分子药物,无论是直接还是间接的,都是针对膜蛋白的。膜蛋白阵列将成为药物筛选和学术研究实验室研究蛋白质与脂质、蛋白质与膜蛋白相互作用以及治疗药物的重要工具。虽然其他微阵列技术如DNA和抗体微阵列已经发展得很好,但膜蛋白微阵列还不能满足生物医学研究和药物筛选的需要。生命生物科学公司(LBSI)计划开发一种商业上可行的膜蛋白阵列系统,通过克服现有的技术障碍,能够以高复用和高通量的方式研究膜蛋白功能和相互作用。第一阶段的研究将集中于开发微阵列平台,并验证该平台对生产功能性膜蛋白阵列的普遍适用性。在第二阶段,我们将把系统扩展到更多的G蛋白偶联受体(GPCRs)微阵列,并整合一个高灵敏度的检测系统,以构成一个完整的膜蛋白分析平台,用于蛋白质功能分析和药物筛选应用。该平台将大大加快蛋白质-脂质、蛋白质-膜蛋白、药物-膜蛋白以及药物-膜相互作用的研究,并将有助于开发和筛选针对多种疾病状态的药物,包括癌症、炎症性疾病、传染病、心脏病和肾脏疾病。
与公共卫生相关:生物膜蛋白在所有生命系统中都发挥着重要作用。发展膜蛋白阵列的拟议研究满足了膜蛋白功能和药物筛选和表征领域的重要需求。膜蛋白阵列将用于开发有效和安全的治疗药物,用于治疗多种疾病,如癌症、糖尿病、炎症和心脏功能障碍。
英文摘要
DESCRIPTION (provided by applicant): Membrane proteins are an essential component of intercellular signaling pathways. The overwhelming majority of small molecule drugs, either directly or indirectly, target membrane proteins. Arrays of membrane proteins would be important tools in drug screening and academic research laboratories in studies of interactions between proteins and lipids, proteins and membrane proteins, as well as therapeutic drugs. Although other microarrays technologies such as DNA and antibody microarrays have been well- developed, membrane protein microarray has been under-developed to fulfill the needs in biomedical research and drug screening. Life BioScience Inc. (LBSI) proposes to develop a commercially viable membrane protein array system capable of studying membrane protein function and interactions in a high multiplexed and high throughput manner by overcoming current technical barriers. Phase I studies will focus on developing microarray platform and validating the general applicability of the platform to produce functional membrane protein arrays. In Phase II we will expand the system to higher multiplex G-protein-coupled receptors (GPCRs) microarrays and incorporate a high sensitivity detection system to comprise a complete membrane protein assay platform for protein functional analysis and drug screening applications. This platform will drastically accelerate investigations of protein-lipid, protein-membrane protein, drug-membrane protein, and drug-membrane interactions, and will be useful in the development and screening of drugs targeting a variety of disease states, including cancer, inflammatory diseases, infectious diseases, heart disease, and kidney disease.
PUBLIC HEALTH RELEVANCE: Biological membrane proteins play an important role in all living systems. The proposed research in developing membrane protein arrays addresses important needs in the areas of membrane protein function and drug screening and characterization. The membrane protein arrays will be useful in the development of effective and safe therapeutic agents for the treatment of wide range diseases such as cancer, diabetes, inflammation, and cardiac dysfunction.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Developing an integrated pipeline for routine generation of orthogonal GPCR-targeting nanobodies
-
批准号:10603669
-
项目类别:
-
资助金额:$21.86万
-
财政年份:2023
-
负责人:XICHUN ZHOU
-
依托单位:
Plasmonic Glycan Arrays for Highly Sensitive Detection of Glycan-binding Proteins
-
批准号:10081148
-
项目类别:
-
资助金额:$22.29万
-
财政年份:2020
-
负责人:XICHUN ZHOU
-
依托单位:
Development of safe and effective immunotherapeutics for treatment of opioid abuse and overdose
-
批准号:10010998
-
项目类别:
-
资助金额:$22.49万
-
财政年份:2020
-
负责人:XICHUN ZHOU
-
依托单位:
IGF::OT::IGF Single domain antibodies for detection and imaging of modified RNA nucleosides
-
批准号:9571729
-
项目类别:
-
资助金额:$24.99万
-
财政年份:2017
-
负责人:XICHUN ZHOU
-
依托单位:
Molecularly self-assembled multi-functional DNA Origami nanostructure for safe and effective siRNA delivery
-
批准号:8834280
-
项目类别:
-
资助金额:$17.07万
-
财政年份:2014
-
负责人:XICHUN ZHOU
-
依托单位:
Conjugation Kits for Facile Preparation of Multivalent Glyco-nanoparticles
-
批准号:7326631
-
项目类别:
-
资助金额:$9.99万
-
财政年份:2007
-
负责人:XICHUN ZHOU
-
依托单位:
Novel 3-dimensional platform for high-throughput glycomics discovery
-
批准号:7218271
-
项目类别:
-
资助金额:$10.18万
-
财政年份:2007
-
负责人:XICHUN ZHOU
-
依托单位:
Portable, rapid and user-friendly diagnostic system for chemical threat exposure
-
批准号:7220132
-
项目类别:
-
资助金额:$10.0万
-
财政年份:2006
-
负责人:XICHUN ZHOU
-
依托单位:
海外基金